Short- and long-term outcomes of local excision with adjuvant radiotherapy in high-risk T1 rectal cancer patients

Abdullah Al-Sawat1, Jung Hoon Bae2, Hyun Ho Kim3, Chul Seung Lee2, Seung Rim Han2, Yoon Suk Lee2, Hyeon-Min Cho3, Hong Seok Jang4, In Kyu Lee2

1Department of Surgery, College of Medicine, Taif University, Taif, Saudi Arabia
2Division of Colorectal Surgery, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Division of Colorectal Surgery, Department of Surgery, St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
4Department of Radiation Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

INTRODUCTION

The standard of care for early rectal cancer is radical surgery; namely, total mesorectal excision (TME), which carries a high risk of postoperative morbidities and influences the patients’ quality of life [1]. Low anterior resection syndrome and stoma formation can negatively affect bowel function [2,3], along with various aspects of sexual dysfunction, urological difficulties, and psychological disturbances [1].

Local excision for early rectal cancer was restricted to...
patients with contraindications to radical surgery or to accept procedure-related recurrence and death [4]. However, with the advancements in early rectal cancer assessment modalities, the improvements in the techniques used to perform local excision and adjuvant therapy for selected patients, and the decreased postoperative morbidity and incidence of stoma formation, local excision has become an alternative to radical surgery [5,6]. However, with the advances in early rectal cancer assessment modalities, the improvements in the techniques used to perform local excision and adjuvant therapy for selected patients, and the decreased postoperative morbidity and incidence of stoma formation, local excision has become an alternative to radical surgery [5,6]. However, with the advances in early rectal cancer assessment modalities, some centers perform transanal endoscopic microsurgery (TEM) for full-thickness assessment due to the uncertainty of the preoperative diagnosis and staging [7].

Several studies have reported a relatively high recurrence rate after transanal local excision (TLE) for early rectal cancer [8-10]. The primary concern associated with disease recurrence is the presence of high-risk histopathological features, which increases the risk of lymph node involvement and recurrence. This concern has been studied extensively over the past few decades. Researchers have reported that cancer type, lymphovascular invasion (LVI), depth, and invasion width carry a high recurrence risk [11,12]. However, adjuvant chemoradiotherapy significantly decreases the incidence of local recurrence [13]: to achieve this low recurrence rate, multidisciplinary treatment is needed for selected patients and an intensive surveillance program must be implemented [14,15]. Interestingly, Borstlap et al. [16] reported in their meta-analysis that the local recurrence rates in T1 rectal cancer between patients with TLE with adjuvant therapy and those who underwent radical surgery were comparable.

As only a few studies in the literature have addressed the usefulness of radiotherapy after local excision for early rectal cancer, we aimed to assess the postoperative complications and morbidity rates of radiation therapy following local excision in pathological stage (p) T1 rectal adenocarcinoma patients with unfavorable histological features, and compare the oncological outcomes with those of the radical resection group.

**METHODS**

A retrospective analysis of the medical records of 78 early rectal cancer patients who underwent local excision followed by adjuvant radiotherapy or radical surgery for T1 rectal cancer with high-risk histological features was performed from April 2010 to July 2020 at Yeouido St. Mary’s Hospital, Seoul St. Mary’s Hospital, and St. Vincent Hospitals. This study was approved by the Institutional Review Board of the College of Medicine, The Catholic University of Korea (No. KC21RASI0391). It was performed in accordance with the Declaration of Helsinki and written informed consent was waived due to its retrospective nature.

**Patient selection**

Patients with a histologically confirmed adenocarcinoma within 10 cm from the anal verge (AV); pT1 high-risk features, including a poorly or undifferentiated adenocarcinoma; a tumor size of ≥3 cm; a positive resection margin; a lymphatic, vascular, or perineural invasion; or a submucosal invasion of ≥SM2 were included in our study. Patients who had low-risk T1 rectal cancer, carcinoma in situ (Tis), another primary cancer, upper rectal cancer, or refusing adjuvant radiotherapy after TLE were excluded from our analysis (Fig. 1).

**Local excision**

Endoscopic biopsy, polypectomy, endoscopic mucosal resection, or endoscopic submucosal dissection (ESD) was performed prior to attempting local excision. We reviewed the histopathological results of biopsy specimens to obtain an accurate diagnosis and to assess for unfavorable features. Clinical and radiological assessments were performed, including digital rectal examination and proctoscopy, to identify the lesion size, location, and accessibility for transanal excision plus abdominopelvic CT and pelvic MRI for staging. Therefore,

---

**Fig. 1.** A flowchart of the research. A total of 78 patients were enrolled in the study. 23 patients were excluded: 37 patients (67.3%) underwent radical resection, and 18 patients (32.7%) had local excision with adjuvant radiotherapy. pT1, pathological stage T1.
local excision is considered for both diagnostic and therapeutic purposes. However, some patients underwent upfront radical resection due to patient's preference or surgeon's experience (Fig. 2).

Post local excision follow-up
A multidisciplinary team reviewed the final histopathological results of local excision to determine whether the patient was suitable for adjuvant radiotherapy or radical surgery according to the histopathological features and comorbidity, considering the patient's preference and surgeon's experience.

Surveillance
After 3 months, the patients who underwent local excision and adjuvant radiotherapy underwent follow-up sigmoidoscopy and abdominopelvic CT. When there are no signs of recurrence, the patients underwent sigmoidoscopy and abdominopelvic CT every 3 months for the first 3 years, every 6 months for the next 2 years, and then annually. Clinical and endoscopic evaluation, plus carcinoembryonic antigen testing, abdominopelvic CT, or pelvic MRI were carried out at each visit.

Outcomes
Data on patient's demographic characteristics (sex, age, and body mass index [BMI]); tumor size; distance from the AV; margin and submucosal invasion; histological types; lymphatic, vascular, and perineural invasion; duration of follow-up; recurrence; postoperative complications; and stoma status were obtained.

Short-term outcomes were defined as morbidity that occurred during the first 30 days postoperatively. Meanwhile, long-term outcomes referred to the oncological outcomes, including recurrence and metastasis. Overall survival (OS) was defined as the period from the date of surgery to the time of death. Patients were censored at the date that they were last known to be alive (last clinic or investigation attendance). Disease-free survival (DFS) was defined as the period from the date of surgery to the time of disease recurrence (local or distant).

Statistics
Categorical variables were analyzed using the chi-square test. Continuous variables were expressed as mean ± standard deviation and were compared using the Student t-test. Patients' characteristics and follow-up results were compared between the local and radical groups; the DFS was analyzed using the Kaplan-Meier curve. Statistical significance was set at P < 0.05. Statistical analyses were performed using IBM SPSS Statistics ver. 24.0 (IBM Corp., Armonk, NY, USA).

RESULTS
Patients' characteristics
Fifty-five patients were enrolled in this study and were divided into the radical resection group (37 patients) and local excision group (18 patients). Their mean age was 61.98 ± 9.97 years; of the total participants, 65.5% were male and 34.5% were female. No difference was found in the baseline characteristics (age, sex, and BMI). The mean tumor distances from the AV were 7.24 ± 2.5 cm and 4.83 ± 2.5 cm in the radical group and local excision group, respectively, which showed a significant difference (P < 0.002). In the radical group, 1 patient underwent an abdominopelvic resection (APR), 4 underwent an intersphincteric resection, and 32 underwent a low anterior resection (Table 1). In the local excision group, 12 patients
underwent a TEM, 4 underwent a TLE, and 2 underwent an ESD. No difference was found in the baseline characteristics among the different approaches of local excision (Table 2).

Pathology
The high-risk features were measured; no significant difference was found between the radical and local excision groups. Furthermore, no difference was observed in the high-risk features in contrast to the different local excision approaches. One patient with a positive resection margin was identified (5.6%) in the local excision group after TLE; however, the difference was not significant compared with the radical resection group. No difference was found in the histological types. The LVI in the local excision group was insignificant compared with that in the radical resection group, which had seven patients with positive lymphatic invasion and five with vascular invasion. With regard to the submucosal depth of invasion, a significant difference was observed between the 2 groups. In the radical resection group, 2 patients (5.4%) had SM2 invasion, while 33 (89.2%) had SM3 invasion. In the local excision group, 10 patients (55.6%) had SM2 and 8 (44.4%) had SM3 invasion ($P < 0.001$) (Table 1).

Postoperative morbidity and mortality
Within the 30-day postoperative period, 10 patients (27.0%) in the radical surgery group developed some complications (ileostomy prolapse, 1; anastomotic leakage, 1; anastomotic stricture, 1; left ureteric injury, 1; ileus, 2; wound infection, 1; neuropathic bladder, 1; erectile dysfunction, 1; and fecal incontinence due to high stool frequency, 1). However, no

### Table 1. Patients’ characteristics

| Variable                  | Radical surgery | Local excision | P-value |
|---------------------------|-----------------|----------------|---------|
| No. of patient            | 37              | 18             |         |
| Sex                       |                 |                |         |
| Male                      | 25 (67.6)       | 11 (61.1)      | 0.637   |
| Female                    | 12 (32.4)       | 7 (38.9)       |         |
| Age (yr)                  | 61.62 ± 8.8     | 62.72 ± 12.1   | 0.705   |
| Body mass index (kg/m²)   | 24.07 ± 2.3     | 24.47 ± 3.7    | 0.631   |
| Anal verge (cm)           | 7.24 ± 2.5      | 4.83 ± 2.5     | 0.002   |
| Surgery type              |                 |                | <0.001  |
| APR                       | 1 (2.7)         | 0 (0)          |         |
| LATA                      | 4 (10.8)        | 0 (0)          |         |
| LAR                       | 32 (86.5)       | 0 (0)          |         |
| TEM                       | 0 (0)           | 12 (66.7)      |         |
| TLE                       | 0 (0)           | 4 (22.2)       |         |
| ESD                       | 0 (0)           | 2 (11.1)       |         |
| High-risk features        |                 |                | 0.288   |
| 1                         | 19 (51.4)       | 10 (55.6)      |         |
| 2                         | 16 (43.2)       | 5 (27.8)       |         |
| ≥3                        | 2 (5.4)         | 3 (16.7)       |         |
| Tumor size (cm)           | 1.8 ± 0.8       | 1.8 ± 0.8      | 0.967   |
| Tumor size                |                 |                | 0.651   |
| <3 cm                     | 32 (86.5)       | 17 (94.4)      |         |
| ≥3 cm                     | 5 (13.5)        | 1 (5.6)        |         |
| Margin invasion           |                 |                | 0.327   |
| –                         | 37 (100)        | 17 (94.4)      |         |
| +                         | 0 (0)           | 1 (5.6)        |         |
| SM depth (μm)             | 3,312.1 ± 1,800.2 | 2,394.4 ± 1,025.2 | 0.050   |
| SM depth (layer)          |                 |                | <0.001  |
| SM1                       | 0 (0)           | 0 (0)          |         |
| SM2                       | 2 (5.4)         | 10 (55.6)      |         |
| SM3                       | 33 (89.2)       | 8 (44.4)       |         |
| Unknown                   | 2 (5.4)         | 0 (0)          |         |
| Histologic type           |                 |                | 0.499   |
| Well differentiated       | 10 (27)         | 8 (44.4)       |         |
| Moderately differentiated | 25 (67.6)       | 10 (55.6)      |         |
| Poorly differentiated     | 1 (2.7)         | 0 (0)          |         |
| Undifferentiated          | 1 (2.7)         | 0 (0)          |         |
| Lymphatic invasion        |                 |                | 0.208   |
| –                         | 29 (78.4)       | 11 (61.1)      |         |
| +                         | 8 (21.6)        | 7 (38.9)       |         |
| Vascular invasion         |                 |                | 0.098   |
| –                         | 34 (91.9)       | 13 (72.2)      |         |
| +                         | 3 (8.1)         | 5 (27.8)       |         |
| Perineural invasion       |                 |                | >0.999  |
| –                         | 35 (94.6)       | 18 (100)       |         |
| +                         | 2 (5.4)         | 0 (0)          |         |
| Follow-up (mo)            | 60.68 ± 33.40   | 36.56 ± 31.53  | 0.013   |
| Adjuvant treatment        |                 |                | <0.001  |
| None                      | 37 (100)        | 0 (0)          |         |
| Radiotherapy              | 0 (0)           | 7 (38.9)       |         |
| CCRT                      | 0 (0)           | 11 (61.1)      |         |

Values are presented as number only, number (%), or mean ± standard deviation. APR, abdominoperineal resection; LATA, laparoscopic abdominal transanal proctosigmoidectomy; LAR, low anterior resection; TEM, transanal endoscopic microsurgery; TLE, transanal local excision; ESD, endoscopic submucosal dissection; SM, submucosa; CCRT, concurrent chemoradiation therapy.
complications were reported in the local excision group, indicating a significant difference between the 2 groups (P = 0.021). Moreover, the rates of stoma formation were significantly higher in the radical surgery group than in the local excision group (P = 0.003). A total of 17 patients (45.9%) had a temporary stoma in the radical surgery group, while none in the local excision group. By contrast, one patient in each group had a permanent stoma. Meanwhile, none of the patients in either group died 30 days after the surgery.

### Oncological outcomes

The overall median follow-up was 52.78 ± 34.46 months (60.68 ± 33.40 months in the radical group and 36.56 ± 31.53 months in the local excision group, P = 0.013). Clinical recurrence was not significantly different between radical excision and local excision with adjuvant therapy (P = 0.103). However, 2 patients who underwent local excision experienced disease recurrence. Specifically, recurrence occurred in the TLE subgroup but not after undergoing TEM. One patient had distant metastasis after 41 months of follow-up, while 1 patient had local recurrence with distant metastasis after 14 months of follow-up. The patient who had local recurrence underwent salvage radical resection with a permanent stoma, and the other patient with distant metastasis received palliative chemotherapy. These 2 patients had 3 high-risk features based on their histopathological reports. One patient had submucosal (SM3) depth invasion, vascular invasion, and mucinous component. The second patient had positive excisional margins, lymphatic invasion, and vascular invasion (Table 2).

The OS rate was similar in both groups (P = 0.301). With regard to the DFS, the analysis showed that the radical group had a superior tendency compared with the local excision group, but the difference was not significant (P = 0.076) (Table 3). Vascular invasion was a significantly poor prognostic factor for DFS (P = 0.033). Presence of 3 or more high-risk features was associated with poor DFS (P = 0.002) (Fig. 3).

### Table 2. Local excision approaches

| Variable | TEM (n = 12) | TLE (n = 4) | ESD (n = 2) | P-value |
|----------|--------------|-------------|-------------|---------|
| Age (yr) | <65 6 (50.0) 2 (50.0) 1 (50.0) | >0.999 |
|          | ≥65 6 (50.0) 1 (50.0) | |
| Sex      | Male 8 (66.7) 2 (50.0) 1 (50.0) | 0.792 |
|          | Female 4 (33.3) 2 (50.0) 1 (50.0) | |
| High-risk features | 1 5 (41.7) 0 (0) 2 (100) | 0.147 |
|          | 2 1 (8.3) 2 (50.0) 0 (0) | |
|          | ≥3 0 (0) | 0 (0) | |
| Tumor size (cm) | <3 11 (91.7) 4 (100) 2 (100) | 0.767 |
|          | ≥3 1 (8.3) 0 (0) 0 (0) | |
| Margin invasion | – 12 (100) 3 (75.0) 2 (100) | 0.157 |
|          | + 0 (0) 1 (25.0) 0 (0) | |
| SM depth (layer) | SM1 0 (0) 0 (0) 0 (0) | 0.407 |
|          | SM2 6 (50.0) 2 (50.0) 2 (100) | |
|          | SM3 6 (50.0) 2 (50.0) 0 (0) | |
| Histologic type | Well differentiated 5 (41.7) 1 (25.0) 2 (100) | 0.207 |
|          | Moderately differentiated 7 (58.3) 3 (75.0) 0 (0) | |
|          | Poorly differentiated 0 (0) 0 (0) 0 (0) | |
|          | Undifferentiated 0 (0) 0 (0) 0 (0) | |
| Lymphatic invasion | – 6 (50.0) 3 (75.0) 2 (100) | 0.329 |
|          | + 6 (50.0) 1 (25.0) 0 (0) | |
| Vascular invasion | – 9 (75.0) 2 (50.0) 2 (100) | 0.407 |
|          | + 3 (25.0) 2 (50.0) 0 (0) | |
| Perineural invasion | – 12 (100) 4 (100) 2 (100) | NA |
|          | + 0 (0) 0 (0) 0 (0) | |
| Adjuvant treatment | None 0 (0) 0 (0) 0 (0) | 0.468 |
|          | Radiotherapy 5 (41.7) 2 (50.0) 0 (0) | |
|          | CCRT 7 (58.3) 2 (50.0) 2 (100) | |
| Recurrence | – 12 (100) 2 (50.0) 2 (100) | 0.019 |
|          | + 0 (0) 2 (50.0) 0 (0) | |
| Survival | Alive 12 (100) 4 (100) 2 (100) | NA |
|          | Death 0 (0) 0 (0) 0 (0) | |
| Primary intervention | Polypectomy 1 (8.3) 1 (25.0) 0 (0) | 0.145 |
|          | EMR 4 (33.3) 1 (25.0) 0 (0) | |
|          | ESD 1 (8.3) 1 (25.0) 2 (100) | |
|          | Surgery 6 (50.0) 1 (25.0) 0 (0) | |
| Recurrence management | Salvage radical surgery 0 (0) 1 (50.0) 0 (0) | NA |
|          | Palliative chemotherapy 0 (0) 1 (50.0) 0 (0) | |

### Table 2. Continued

| Variable | TEM (n = 12) | TLE (n = 4) | ESD (n = 2) | P-value |
|----------|--------------|-------------|-------------|---------|
| Recurrence location | Local 0 (0) 0 (0) 0 (0) | NA |
|          | Systematic 0 (0) 1 (50.0) 0 (0) | |
|          | Local and systematic 0 (0) 1 (50.0) 0 (0) | |

Values are presented as number (%). TEM, transanal endoscopic microsurgery; TLE, transanal local excision; ESD, endoscopic submucosal dissection; SM, submucosa; NA, not applicable; CCRT, concurrent chemoradiation therapy; EMR, endoscopic mucosal resection.
Table 3. Univariate analysis

| Variable                      | Disease-free survival (95% CI) | P-value | Overall survival (95% CI) | P-value |
|-------------------------------|-------------------------------|---------|---------------------------|---------|
| **Group**                     |                               |         |                           |         |
| Local                         | Reference                     | 0.076   | Reference                 | 0.301   |
| Radical                       | 0.108 (0.009–1.267)           |         | 2.959 (0.379–23.122)      |         |
| **Sex**                       |                               |         |                           |         |
| Male                          | Reference                     |         | Reference                 |         |
| Female                        | 0.026 (0.001–604.883)         | 0.477   | 0.982 (0.314–3.072)       | 0.975   |
| **Age (yr)**                  |                               |         |                           |         |
| <65                           | Reference                     |         | Reference                 |         |
| ≥65                           | 0.525 (0.047–5.810)           | 0.599   | 0.496 (0.152–1.614)       | 0.244   |
| **High-risk features**        |                               |         |                           |         |
| 1                             | Reference                     |         | Reference                 |         |
| 2                             | 0.001 (0.001–1.407)           | 0.002   |                           |         |
| ≥3                            | 0.001 (0.001–1.055)           |         |                           |         |
| **Body mass index (kg/m²)**   |                               |         |                           |         |
| <25                           | Reference                     |         | Reference                 |         |
| ≥25                           | 2.101 (0.182–24.247)          | 0.552   | 1.844 (0.445–7.634)       | 0.399   |
| **Anal verge (cm)**           |                               |         |                           |         |
| >8                            | Reference                     |         | Reference                 |         |
| ≤8                            | 0.858 (0.077–9.491)           | 0.900   |                           |         |
| **Surgery type**              |                               |         |                           |         |
| APR                           | Reference                     |         | Reference                 |         |
| LATA                          | 1.000 (0.001–1,431,378.699)   | >0.999  |                           | >0.999  |
| LAR                           | 1.000 (0.001–16,530.328)      | >0.999  | 1.000 (0.001–1,212,117.509)| >0.999  |
| TEM                           | 1.000 (0.001–5,568.976)       | >0.999  | 1.000 (0.001–1,271,316.750)| >0.999  |
| TLE                           | 1.000 (0.001–8,462.377)       | >0.999  | 1.000 (0.001–1,525,286.060)| >0.999  |
| ESD                           | 1.000 (0.001–27,705.960)      | >0.999  | 1.000 (0.001–3,058,535.598)| >0.999  |
| **Radical vs. local surgery** |                               |         |                           |         |
| Radical surgery               | Reference                     |         | Reference                 |         |
| Local excision                | 9.296 (0.789–109.475)         | 0.076   | 0.338 (0.043–2.640)       | 0.301   |
| **Tumor size (cm)**           |                               |         |                           |         |
| <3                            | Reference                     |         | Reference                 |         |
| ≥3                            | 3.468 (0.313–38.388)          | 0.311   | 0.041 (0.001–61.346)      | 0.391   |
| **Margin involvement**        |                               |         |                           |         |
| –                             | Reference                     |         | Reference                 |         |
| +                             | 1.000 (0.001–595,053.125)     | >0.999  |                           |         |
| **Lymphatic invasion**        |                               |         |                           |         |
| –                             | Reference                     |         | Reference                 |         |
| +                             | 1.226 (0.111–13.567)          | 0.868   | 0.177 (0.023–1.372)       | 0.097   |
| **Vascular invasion**         |                               |         |                           |         |
| –                             | Reference                     |         | Reference                 |         |
| +                             | 13.704 (1.233–152.359)        | 0.033   | 1.071 (0.236–4.854)       | 0.929   |
| **Perineural invasion**       |                               |         |                           |         |
| –                             | Reference                     |         | Reference                 |         |
| +                             | 0.045 (0.001–73,162,199.76)   | 0.775   | 1.513 (0.192–11.938)      | 0.695   |
| **Radiotherapy**              |                               |         |                           |         |
| –                             | Reference                     |         | Reference                 |         |
| +                             | 770.115 (0.001–6,425,223.963) | 0.414   | 0.299 (0.038–2.336)       | 0.250   |
| **Complication**              |                               |         |                           |         |
| –                             | Reference                     |         | Reference                 |         |
| +                             | 0.031 (0.001–2,049.625)       | 0.540   | 1.171 (0.352–3.899)       | 0.797   |
| **Stomy formation**           |                               |         |                           |         |
| –                             | Reference                     |         | Reference                 |         |
| +                             | 0.017 (0.001–212.424)         | 0.398   | 1.989 (0.640–6.179)       | 0.235   |

CI, confidence interval; APR, abdominoperineal resection; LATA, laparoscopic abdominal transanal proctosigmoidectomy; LAR, low anterior resection; TEM, transanal endoscopic microsurgery; TLE, transanal local excision; ESD, endoscopic submucosal dissection.
DISCUSSION

The management of rectal cancer has improved over the past few decades, and TME without neoadjuvant or adjuvant therapy remains the cornerstone of therapy for early rectal cancer, associated with a decreased incidence of local recurrence and subsequent improvements in patient's survival. Thus, our data showed no recurrence of unfavorable T1 rectal cancer in the radical resection group. Mellgren et al. [17] reported that within the 5-year follow-up, 18% of the patients in the local excision group and none in the radical resection group developed local recurrence. Nevertheless, rectal preservation benefits, low morbidity, less operative time, and the reduced length of hospital stay have made a clinical shift toward less invasive approaches [18].

As no conclusive criteria have been established yet, the selection of patients who will undergo local excision or radical resection remains a challenge during the preoperative period. After conducting an endoscopic biopsy, we aimed to implement local excision in any patient with clinical and radiological T1 rectal cancer to determine the underlying pathology. We revised the criteria used for selecting patients for undergoing local excision and adjuvant radiotherapy. However, clinicians should carefully select the suitable patients and educate them regarding the possible interventions that would be implemented and the complications that might occur, as the oncological outcomes for salvage radical resection after local excision are poorer than those of the initial radical resection [8].

The different techniques for local excision applied in this study depend on the surgeon's experience and preference. Approximately 12 of the patients from the local excision group (66.7%) underwent TEM performed by the same surgeon. Indeed, TEM is more effective in obtaining negative excisional margins and better DFS than TLE. A meta-analysis [19] of 11 studies included 1,191 patients, who were divided into the TEM group (514 patients), radical resection group (291 patients), and the TLE group (386 patients). Results of the meta-analysis showed that radical resection was more superior in obtaining a negative margin; moreover, TLE was reported to be inferior to TEM. The TLE subgroup's recurrence rate in the present study was consistent with that in the previous studies, which reported a higher recurrence rate after conducting a TLE [8].

Despite the recent advances in local excision techniques, unfavorable histological features are associated with the risk of recurrence and affect patient's survival.
concluded that a universal criterion for response assessment was approximately 30%. Other studies have shown a 50%–60% locoregional treatment failure of the watch and wait approach. Habr-Gama et al. [26] reported that the risk of a complete clinical response but not a complete pathological viable residual tumor in the rectum of a patient who achieved challenge and pitfall of this strategy are that it may leave a neoadjuvant therapy and radical resection. The primary must be determined. These patients have the chance to implementing this approach, the possible oncological outcomes nonoperative “watch and wait” approach. However, before recurrence, a meticulous surveillance must be mandated. The short-term benefits of local excision must be counterbalanced with its oncological outcomes. Uncertainty persists concerning the oncological appropriateness of local excision for rectal cancer. In our study, no complications were reported following the different local excision techniques or temporary stoma maturation (P = 0.021 and P = 0.003, respectively). However, a permanent stoma was made in the local excision group due to local recurrence, which was managed with APR. By contrast, recurrence occurred in 2 patients from the TLE subgroup who had more than 2 high-risk features in their final histopathological evaluation. The first patient experienced local recurrence detected during surveillance and was managed with radical resection. Later, the patient developed distant metastasis to the lungs, ribs, and vertebrae and underwent palliative chemotherapy. The second patient had lung metastasis on follow-up and received systemic chemotherapy. Thus, the group who had radical resection showed a superior tendency to develop recurrence compared with the group who had local excision with radiotherapy, but the difference was not significant (P = 0.076). This result is consistent with that of previously published studies.

The present study has some limitations. First, our review was retrospective in nature. Second, the surgical intervention depends on the surgeon's experience and patient preference; therefore, the potential of selection bias exists. Third, it has a limited sample size. Lastly, we defined SM1 as tumor invasion in the submucosa of less than 1,000 μm, SM2 as equal to 1,000 μm or more but less than 2,000 μm, and SM3 as equal to 2,000 μm or more. Thus, the pathological results of the 3 hospitals were not standardized. However, the results are promising for patients with less than 3 high-risk T1 rectal cancer features who prefer local excision and adjuvant radiotherapy instead of radical resection to avoid procedure morbidity and improve the quality of life; in order to achieve an acceptable low risk of recurrence, a meticulous surveillance must be mandated. Our study concludes that local excision with adjuvant radiotherapy is a better treatment option to avoid complications and stoma formation. Furthermore, local excision with adjuvant radiotherapy is an alternative option for patients with T1 rectal cancer with fewer than 3 high-risk features.

ACKNOWLEDGEMENTS

Conflict of Interest
No potential conflict of interest relevant to this article was reported.
REFERENCES

1. Borstlap WA, Tanis PJ, Koedam TW, Marijnen CA, Cunningham C, Dekker E, et al. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. BMC Cancer 2016;16:513.

2. Creese AD, Lonie JM, Trollope AF, Vangaveti VN, Ho YH. A meta-analysis of the prevalence of Low Anterior Resection Syndrome and systematic review of risk factors. Int J Surg 2018;56:234-41.

3. Ha RK, Park SC, Park B, Park SS, Sohn DK, Chang HJ, et al. Comparison of patient-reported quality of life and functional outcomes following laparoscopic and transanal total mesorectal excision of rectal cancer. Ann Surg Treat Res 2021;101:1-12.

4. Nash GM, Weiser MR, Guillem JG, Temple LK, Shia J, Gonen M, et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum 2009;52:577-82.

5. Balyasnikova S, Read J, Tait D, Wotherspoon A, Swift I, Cunningham D, et al. The results of local excision with or without postoperative adjuvant chemoradiotherapy for early rectal cancer among patients choosing to avoid radical surgery. Colorectal Dis 2017;19:139-47.

6. Hwang Y, Yoon YS, Bong JW, Choi HY, Song IH, Lee JL, et al. Long-term transanal excision outcomes in patients with T1 rectal cancer: comparative analysis of radical resection. Ann Coloproctol 2019;35:194-201.

7. Morino M, Allaix ME. Transanal endoscopic microsurgery: what indications in 2013? Gastroenterol Rep (Oxf) 2013;1:75-84.

8. You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database Ann Surg 2007;245:726-33.

9. Patel SA, Chen YH, Hornick JL, Catalano P, Nowak JA, Zuckenberg LR, et al. Early-stage rectal cancer: clinical and pathologic prognostic markers of time to local recurrence and overall survival after resection. Dis Colon Rectum 2014;57:449-59.

10. Storenes T, Wibe A, Nesbakken A, Myklebust TÅ, Endreseth BH. National early rectal cancer treatment revisited. Dis Colon Rectum 2016;59:623-9.

11. Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002;45:200-6.

12. Toh EW, Brown P, Morris E, Botterill I, Quirke P. Area of submucosal invasion and width of invasion predicts lymph node metastasis in pT1 colorectal cancers. Dis Colon Rectum 2015;58:393-400.

13. Cutting JE, Hallam SE, Thomas MG, Messenger DE. A systematic review of local excision followed by adjuvant therapy in early rectal cancer: are pT1 tumours the limit? Colorectal Dis 2018;20:854-63.

14. Suzuki T, Sadahiro S, Tanaka A, Okada K, Saito G, Miyakita H, et al. Outcomes of local excision plus chemoradiotherapy in patients with T1 rectal cancer. Oncology 2018;95:246-50.

15. Jones HJ, Goodbrand S, Hompes R, Mortensen N, Cunningham C. Radiotherapy after local excision of rectal cancer may offer reduced local recurrence rates. Colorectal Dis 2019;21:451-9.

16. Borstlap WA, Coeymans TJ, Tanis PJ, Marijnen CA, Cunningham C, Bemelman WA, et al. Meta-analysis of oncological outcomes after local excision of pT1-2 rectal cancer requiring adjuvant (chemo)radiotherapy or completion surgery. Br J Surg 2016;103:1105-16.

17. Mellgren A, Sirivongs P, Rothenberger DA, Madoff RD, García-Aguilar J. Is local excision adequate therapy for early rectal cancer? Dis Colon Rectum 2000;43:1064-74.

18. Palma P, Horisberger K, Joos A, Rothenhoefer S, Willeke F, Post S. Local excision of early rectal cancer: is transanal endoscopic microsurgery an alternative to radical surgery? Rev Esp Enferm Dig 2009;101:172-8.

19. Sgourakis G, Lanitis S, Gockel I, Kontovounisios C, Karaliotas C, Tsiftsi K, et al. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-
analysis and meta-regression analysis of outcomes. Am Surg 2011;77:701-72.
20. Kikuchi R, Takano M, Takagi K, Fujimoto N, Nozaki R, Fujiyoshi T, et al. Management of early invasive colorectal cancer: risk of recurrence and clinical guidelines. Dis Colon Rectum 1995;38:1286-95.
21. Min BS, Kim NK, Ko YT, Lee KY, Baek SH, Cho CH, et al. Long-term oncologic results of patients with distal rectal cancer treated by local excision with or without adjuvant treatment. Int J Colorectal Dis 2007;22:1325-30.
22. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985;89:328-36.
23. Sticca RP, Rodriguez-Bigas M, Penetrante RB, Petrelli NJ. Curative resection for stage I rectal cancer: natural history, prognostic factors, and recurrence patterns. Cancer Invest 1996;14:491-7.
24. Hakiman H, Pendola M, Fleshman JW. Replacing transanal excision with transanal endoscopic microsurgery and/or transanal minimally invasive surgery for early rectal cancer. Clin Colon Rectal Surg 2015;28:38-42.
25. Duek SD, Issa N, Hershko DD, Krausz MM. Outcome of transanal endoscopic microsurgery and adjuvant radiotherapy in patients with T2 rectal cancer. Dis Colon Rectum 2008;51:979-84.
26. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240:711-8.
27. Nakagawa WT, Rossi BM, de O Ferreira F, Ferrigno R, David Filho WJ, Nishimoto IN, et al. Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? Ann Surg Oncol 2002;9:568-73.
28. Dalton RS, Velineni R, Osborne ME, Thomas R, Harries S, Gee AS, et al. A single-centre experience of chemoradiation therapy for rectal cancer: is there potential for nonoperative management? Colorectal Dis 2012;14:567-71.
29. Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017;2:501-13.